What’s Ahead for Codexis, Inc. (CDXS) After Achieving 52-Week High?

May 22, 2018 - By Vivian Currie

Codexis, Inc. (NASDAQ:CDXS) Logo

Investors sentiment decreased to 2.17 in 2017 Q4. Its down 0.03, from 2.2 in 2017Q3. It worsened, as 3 investors sold Codexis, Inc. shares while 15 reduced holdings. 12 funds opened positions while 27 raised stakes. 28.02 million shares or 9.42% more from 25.60 million shares in 2017Q3 were reported.
California State Teachers Retirement Sys has 64,489 shares for 0% of their portfolio. Balyasny Asset Management Lc holds 0% or 11,845 shares. Morgan Stanley reported 91,201 shares stake. Eam Ltd Liability Co invested in 87,275 shares or 0.1% of the stock. Bnp Paribas Arbitrage Sa stated it has 0% in Codexis, Inc. (NASDAQ:CDXS). Fmr Limited Liability Corp holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 828,974 shares. Voya Management Ltd Liability invested in 0% or 18,236 shares. Rhumbline Advisers has 35,893 shares for 0% of their portfolio. Northern Trust owns 429,439 shares. Howe Rusling holds 0.01% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 5,000 shares. Legal And General Gp Public Ltd Co stated it has 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Barclays Public Ltd Company reported 0% in Codexis, Inc. (NASDAQ:CDXS). Ameritas Investment Partners Inc holds 2,608 shares or 0% of its portfolio. First Light Asset Mgmt Lc reported 1.84% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Jpmorgan Chase & invested in 0% or 8,800 shares.

Since March 21, 2018, it had 0 buys, and 7 selling transactions for $1.73 million activity. 22,465 shares were sold by NICOLS JOHN J, worth $259,828. Aldridge Michael D. sold 22,000 shares worth $283,945. 41,666 shares valued at $464,384 were sold by WOLF DENNIS P on Monday, March 26. Another trade for 10,206 shares valued at $124,683 was sold by KELLEY BERNARD J. The insider Smith David V sold $62,213. 20,000 shares were sold by Lalonde James, worth $259,930 on Monday, May 14.

The stock of Codexis, Inc. (NASDAQ:CDXS) hit a new 52-week high and has $14.72 target or 4.00 % above today’s $14.15 share price. The 6 months bullish chart indicates low risk for the $753.35M company. The 1-year high was reported on May, 22 by Barchart.com. If the $14.72 price target is reached, the company will be worth $30.13M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.35% or $0.05 during the last trading session, reaching $14.15. About 155,670 shares traded. Codexis, Inc. (NASDAQ:CDXS) has risen 125.77% since May 22, 2017 and is uptrending. It has outperformed by 114.22% the S&P500.

Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on August, 8. They expect $-0.03 EPS, up 76.92 % or $0.10 from last year’s $-0.13 per share. After $-0.10 actual EPS reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -70.00 % EPS growth.

Codexis, Inc. (NASDAQ:CDXS) Ratings Coverage

Among 2 analysts covering Codexis (NASDAQ:CDXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Codexis had 2 analyst reports since March 12, 2018 according to SRatingsIntel. Stephens initiated it with “Buy” rating and $1600 target in Wednesday, May 16 report. The firm has “Buy” rating given on Monday, March 12 by H.C. Wainwright.

More notable recent Codexis, Inc. (NASDAQ:CDXS) news were published by: Seekingalpha.com which released: “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript” on May 11, 2018, also Fool.com with their article: “3 High-Growth Stocks That Are Just Getting Started” published on May 12, 2018, Globenewswire.com published: “Codexis to Hold First Quarter 2018 Conference Call on May 10” on May 03, 2018. More interesting news about Codexis, Inc. (NASDAQ:CDXS) were released by: Globenewswire.com and their article: “Codexis Reports First Quarter 2018 Financial Results” published on May 10, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 16, 2018.

Codexis, Inc. discovers, develops, and sells protein catalysts. The company has market cap of $753.35 million. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening. It currently has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

Codexis, Inc. (NASDAQ:CDXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: